JP2011520846A - 多発性骨髄腫の治療 - Google Patents

多発性骨髄腫の治療 Download PDF

Info

Publication number
JP2011520846A
JP2011520846A JP2011508943A JP2011508943A JP2011520846A JP 2011520846 A JP2011520846 A JP 2011520846A JP 2011508943 A JP2011508943 A JP 2011508943A JP 2011508943 A JP2011508943 A JP 2011508943A JP 2011520846 A JP2011520846 A JP 2011520846A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
cells
treatment
acceptable salt
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011508943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011520846A5 (OSRAM
Inventor
エンリケ・オシオ
アタナシオ・パンディエラ
ヘズス・サン・ミゲル
パブロ・マニュエル・アヴィレス・マリン
Original Assignee
ファルマ・マール・ソシエダード・アノニマ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファルマ・マール・ソシエダード・アノニマ filed Critical ファルマ・マール・ソシエダード・アノニマ
Publication of JP2011520846A publication Critical patent/JP2011520846A/ja
Publication of JP2011520846A5 publication Critical patent/JP2011520846A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011508943A 2008-05-16 2009-05-18 多発性骨髄腫の治療 Pending JP2011520846A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08380154 2008-05-16
EP08380154.8 2008-05-16
PCT/EP2009/055978 WO2009138509A1 (en) 2008-05-16 2009-05-18 Multiple myeloma treatments

Publications (2)

Publication Number Publication Date
JP2011520846A true JP2011520846A (ja) 2011-07-21
JP2011520846A5 JP2011520846A5 (OSRAM) 2012-07-05

Family

ID=40848780

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011508943A Pending JP2011520846A (ja) 2008-05-16 2009-05-18 多発性骨髄腫の治療

Country Status (12)

Country Link
US (1) US8435992B2 (OSRAM)
EP (1) EP2303274A1 (OSRAM)
JP (1) JP2011520846A (OSRAM)
KR (1) KR20110028454A (OSRAM)
CN (1) CN102065865B (OSRAM)
AU (1) AU2009248039B2 (OSRAM)
CA (1) CA2724206A1 (OSRAM)
IL (1) IL209360A (OSRAM)
MX (1) MX2010012358A (OSRAM)
NZ (1) NZ589270A (OSRAM)
RU (1) RU2519750C2 (OSRAM)
WO (1) WO2009138509A1 (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919493B2 (en) 2000-04-12 2011-04-05 Pharma Mar, S.A. Anititumoral ecteinascidin derivatives
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
GB0117402D0 (en) 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
WO2009140675A2 (en) * 2008-05-16 2009-11-19 Pharma Mar, S.A. Combination therapy with an antitumor alkaloid
WO2011048210A1 (en) 2009-10-22 2011-04-28 Pharma Mar, S.A. PDGFR-α AS RESPONSE MARKER FOR PM00104 TREATMENT
KR101471273B1 (ko) * 2013-01-29 2014-12-11 인제대학교 산학협력단 Ｓｏｄ２를 포함하는 보르테조밉 내성 진단용 바이오 마커 조성물 및 이를 이용한 진단 키트
KR101718800B1 (ko) 2015-01-21 2017-03-24 주식회사 디알나노 약물 및 ｓｉＲＮＡ의 공동―운반용 나노복합체 및 이의 용도
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533532A (ja) * 2000-05-15 2003-11-11 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３の抗腫瘍性類似体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1074243C (zh) * 1997-09-16 2001-11-07 林禾杰 对虾养殖方法
US6124292A (en) * 1998-09-30 2000-09-26 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
AR035842A1 (es) * 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
US6569859B1 (en) * 2000-02-22 2003-05-27 President And Fellows Of Harvard College Synthetic analogs of ecteinascidin-743
GB0229793D0 (en) * 2002-12-20 2003-01-29 Pharma Mar Sa The gene cluster involved in safracin biosynthesis and its uses for genetic engineering
WO2004080477A1 (en) * 2003-03-12 2004-09-23 Dana-Farber Cancer Institute, Inc. Aplidine for multiple myeloma treatment
GB0522082D0 (en) * 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
TW200801513A (en) 2006-06-29 2008-01-01 Fermiscan Australia Pty Ltd Improved process
GB0708691D0 (en) * 2007-05-04 2007-06-13 Pharma Mar Sa Anticancer treatments a

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003533532A (ja) * 2000-05-15 2003-11-11 ファルマ・マール・ソシエダード・アノニマ Ｅｔ−７４３の抗腫瘍性類似体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CSNC200901254021; 石田禎夫: '化学療法' 日本臨牀 第６５巻、第１２号, 2007, ｐ．２２８０-２２８４, 株式会社日本臨牀社 *
JPN6013059933; 石田禎夫: '化学療法' 日本臨牀 第６５巻、第１２号, 2007, ｐ．２２８０-２２８４, 株式会社日本臨牀社 *
JPN6013059935; Ｄ．　Ｅ．　ＢＥＲＧＳＡＧＥＬ　ａｎｄ　Ｄ．　ＰＨＩＬ: 'ＰＬＡＳＭＡ　ＣＥＬＬ　ＭＹＥＬＯＭＡ　Ａｎ　Ｉｎｔｅｒｐｒｅｔｉｖｅ　Ｒｅｖｉｅｗ' Ｃａｎｃｅｒ Ｖｏｌ．３０，　Ｎｏ．６, 1972, ｐ．１５８８-１５９４ *
JPN6013059936; ステッドマン医学大辞典 第５版, 2004, ｐ．１１５５-１１５６, 株式会社メジカルビュー社 *

Also Published As

Publication number Publication date
US20110076343A1 (en) 2011-03-31
KR20110028454A (ko) 2011-03-18
RU2010151660A (ru) 2012-06-27
CN102065865A (zh) 2011-05-18
AU2009248039B2 (en) 2014-07-31
NZ589270A (en) 2011-12-22
AU2009248039A1 (en) 2009-11-19
RU2519750C2 (ru) 2014-06-20
CN102065865B (zh) 2013-03-20
MX2010012358A (es) 2011-01-25
EP2303274A1 (en) 2011-04-06
IL209360A (en) 2015-10-29
IL209360A0 (en) 2011-01-31
CA2724206A1 (en) 2009-11-19
US8435992B2 (en) 2013-05-07
WO2009138509A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
JP2011520846A (ja) 多発性骨髄腫の治療
RU2767664C2 (ru) Комбинированная терапия противоопухолевым алкалоидом
JP6787792B2 (ja) がんの処置のための併用治療
CN105873440B (zh) 抑制tie2激酶的组合物在制备治疗癌症的药物中的用途
US10583129B2 (en) Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer
TWI688387B (zh) 二氫槲皮素或其醫藥上可接受之鹽、或含有彼之組合物的醫藥用途
JP6570512B2 (ja) 新規なＳｔａｔ３阻害剤
JP7246309B2 (ja) 免疫応答を調節するためのオキサビシクロヘプタン
US12116363B2 (en) Combinations for immune-modulation in cancer treatment
AU2023202746A1 (en) Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof
JP2012516354A (ja) 乳癌を治療するための方法及び組成物
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
EP1605937B1 (en) Treatment of proliferative diseases with epothilone derivatives and radiation
JP2020528418A (ja) ＢＥＴ阻害剤及びＢｃｌ−２阻害剤を用いた併用療法
US20130310352A1 (en) Dexamethasone combination therapy
Burger et al. Inhibition of the JAK-STAT3-Mcl-1 Axis by Combining Ruxolitinib with S63845 Completely Prevents Plasmacytoma Growth in the Gp130-Regulated INA-6 Xenograft Mouse Model
TW202430160A (zh) 投予貝魯舒地爾（ｂｅｌｕｍｏｓｕｄｉｌ）治療多發性骨髓瘤之方法
AU2014227478A1 (en) Filanesib combined with pomalidomide displays enhanced anti-tumor activity
AU2021200121A1 (en) Pharmaceutical compositions and use thereof for relieving resistance due to cancer chemotherapy and enhancing effect of cancer chemotherapy
KR20190012118A (ko) 혈관차단제 및 면역 체크포인트 억제제를 포함하는 암 예방 또는 치료용 조성물
EA039621B1 (ru) Комбинация bcl-2 ингибитора и mcl-1 ингибитора, их применения и фармацевтические композиции

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120517

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131203

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140227

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20140306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20141201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160720

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160822